Holly Ahlers
Psychiatric/Mental Health · Sioux Falls, SDNPI 1366948663
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,196 of the $3,715 with a category attached, or 86.0%. It is spread thinly across 14 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,072, 2.1 times the $517 reported in 2021. Among psychiatric/mental health clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $13.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$772
- Neurocrine Biosciences, Inc.$735
- Johnson & Johnson$539
- Alkermes, Inc.$394
- E.r. Squibb & Sons, L.L.C.$385
- Otsuka America Pharmaceutical, Inc.$270
- plus $619 from 8 others
What the payments were for
- Food & beverage$3,19686%
- Education$51914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $772 |
| Neurocrine Biosciences, Inc. | 83 | $735 |
| Johnson & Johnson | 39 | $539 |
| Alkermes, Inc. | 21 | $394 |
| E.r. Squibb & Sons, L.L.C. | 24 | $385 |
| Otsuka America Pharmaceutical, Inc. | 21 | $270 |
| AbbVie | 32 | $213 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $146 |
| Sunovion Pharmaceuticals Inc. | 12 | $121 |
| Axsome Therapeutics, Inc. | 4 | $60 |
| Vanda Pharmaceuticals Inc. | 3 | $40 |
| Lundbeck LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,715 in reported general payments places this provider in the 90th percentile of 77 psychiatric/mental health providers in South Dakota.
See all psychiatric/mental health providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 49 | $167,453 |
| IngrezzaValbenazine Tosylate | 21 | $167,098 |
| VraylarCariprazine Hcl | 84 | $85,906 |
| Invega SustennaPaliperidone Palmitate | 16 | $42,233 |
| RexultiBrexpiprazole | 29 | $39,098 |
| CaplytaLumateperone Tosylate | 18 | $29,720 |
| SaphrisAsenapine Maleate | 15 | $14,473 |
| Clozapine | 148 | $6,741 |
| BelsomraSuvorexant | 26 | $6,022 |
| Paliperidone ErPaliperidone | 62 | $3,658 |
| Aripiprazole | 145 | $2,876 |
| Doxepin Hcl | 23 | $2,304 |
| Lurasidone Hcl | 20 | $2,239 |
| Prazosin Hcl | 127 | $1,818 |
| Gabapentin | 180 | $1,777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada | $394 | $167,45349 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $735 | $167,09821 claims |
| AbbVieVraylar, Saphris | $213 | $100,37999 claims |
| Johnson & JohnsonInvega Sustenna | $539 | $42,23316 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $270 | $39,09829 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $146 | $29,72018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 77 psychiatric/mental health providers in South Dakota.
Other psychiatric/mental health in Sioux Falls
- Nichole JohnsonSioux Falls$5K
- Andria PetersenSioux Falls$5K
- Afton ArtzSioux Falls$2K
- Audrey FuksSioux Falls$2K
- Marie JamesonSioux Falls$761
- Veronica SherwoodSioux Falls$756
- Taylor RobertsSioux Falls$717
- Kaitlyn WalkerSioux Falls$574
- Hannah OttenSioux Falls$376
- Garneth KuiperSioux Falls$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.